<DOC>
	<DOC>NCT02737774</DOC>
	<brief_summary>This is a prospective, open, single-center, phase Ⅱ study to assess the efficacy and safety of alternating Icotinib and chemotherapy for advanced non-small cell lung cancer with EGFR mutation.</brief_summary>
	<brief_title>Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1. Histological or cytological confirmation of nonsmall cell lung cancer (NSCLC) in phase ⅢB or phase Ⅳ. 2. Positive EGFR mutation(19 exon or 21 exon)。 1. Previous usage of EGFRTKI or antibody to EGFR: gefitinib, erlotinib, herceptin, erbitux. 2. Severe systemic disease out of control such as unstable or uncompensated respiratory,cardiac,liver,renal diseases. 3. Allergic to icotinib 4. metastases of spinal cord, meninges or meningeal.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Icotinib</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>EGFR</keyword>
</DOC>